Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: a cross-sectional analysis.

Autor:	Macleod D; International Statistics and Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: david.macleod@lshtm.ac.uk., Shanaube K; Zambart, School of Public Health, University of Zambia, Lusaka, Zambia., Skalland T; HPTN Statistical and Data Management Centre, Seattle, WA, USA., Limbada M; Zambart, School of Public Health, University of Zambia, Lusaka, Zambia., Mandla N; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa., Bwalya J; Zambart, School of Public Health, University of Zambia, Lusaka, Zambia., Schaap A; International Statistics and Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK; Zambart, School of Public Health, University of Zambia, Lusaka, Zambia., Yang B; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa., Donnell D; HPTN Statistical and Data Management Centre, Seattle, WA, USA., Piwowar-Manning E; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Eshleman SH; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Hoddinott G; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa., Bond V; Global Health and Development Department, Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK; Zambart, School of Public Health, University of Zambia, Lusaka, Zambia., Moore A; FHI 360, HIV Prevention Trials Network, Durham, NC, USA., Griffith S; FHI 360, HIV Prevention Trials Network, Durham, NC, USA., Bock P; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa., Ayles H; Zambart, School of Public Health, University of Zambia, Lusaka, Zambia., Fidler S; Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK., Hayes R; International Statistics and Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK., Floyd S; International Statistics and Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
Jazyk:	angličtina
Zdroj:	The lancet. HIV [Lancet HIV] 2022 Nov; Vol. 9 (11), pp. e751-e759.
DOI:	10.1016/S2352-3018(22)00237-5
Abstrakt:	Background: In 2014, UNAIDS set the target that 90% of individuals on antiretroviral therapy (ART) be virally suppressed. Here, we use data from the HPTN 071 (PopART) trial to report whether the introduction of universal testing and treatment has affected viral suppression or treatment adherence among individuals who self-reported they were taking ART, and identify risk factors for these outcomes. Methods: This was a cross-sectional study nested within the randomly selected population cohort of the PopART trial. The trial took place in 21 communities in Zambia and South Africa. Analyses included 3570 HIV-positive participants who were seen at the second follow-up visit in 2016-17 and who self-reported that they were currently taking ART. Viral suppression was defined as HIV RNA of less than 400 copies per mL from a blood sample collected during the cohort visit, and ART adherence was measured using self-reporting (reported as no missed pills in last 7 days). Prevalences of these outcomes were compared across three trial arms using a two-stage approach suitable for clustered data. Each arm consisted of seven communities, with one arm receiving a combination HIV prevention package including immediate ART initiation, one receiving a combination HIV prevention package excluding immediate ART initiation and one arm receving standard of care. Risk factors for each of the outcomes were assessed using logistic regression. Findings: Among the 3570 participants who self-reported that they were currently on ART, 416 (11·7%) of 3554 were not virally suppressed (16 were missing viral suppression status) and 345 (9·7%) of 3566 reported being non-adherent to ART (four were missing adherence status). The proportion not virally suppressed was higher in communities in South Africa (195 [16·4%] of 1191) than in Zambia (221 [9·4%] of 2363). There was no evidence that the prevalence of the outcomes differed between trial arms. There was evidence that men, younger individuals, individuals who reported participating in harmful alcohol use, and those who reported internalised stigma were more likely to be non-adherent, and not virally suppressed. Interpretation: The results assuaged concerns that early ART initiation in a universal testing and treatment setting could lead to reduced adherence and viral suppression. Funding: US National Institute of Allergy and Infectious Diseases (which is a part of the National Institutes of Health), the International Initiative for Impact Evaluation with support from the Bill & Melinda Gates Foundation, US President's Emergency Plan for AIDS Relief, and Medical Research Council UK. Competing Interests: Declaration of interests AM, EP-M, and SHE report funding from the National Institutes of Health (NIH). DD and TS reports funding from the National Institute of Allergy and Infectious Diseases (NIAID) and NIH. DM, SFl, and HA report funding from NIH, the US President's Emergency Plan for AIDS Relief (PEPFAR), the Bill & Melinda Gates Foundation, and the International Initiative for Impact Evaluation. SFid reports participation on a Data and Safety Monitoring Board for the Disasters Emergency Committee HIV vaccine trial. GH reports funding from NIH, NIAID, and the National Institute of Mental Health, the Gates Foundation, South African TB Think Tank, the United States Agency for International Development, Unitaid, Stop TB partnership, and participation on an advisory board for Templeton World Charity Foundation. All other authors declare no competing interests. (Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu